Background Tuberculosis (TB) is preventable and curable but eliminating it has proven
challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential …

Background Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines
will be required to reach global targets and reverse setbacks resulting from the COVID-19 …

Background VRE bacteraemia has a high mortality and continues to defy control. Antibiotic
risk factors for VRE bacteraemia have not been adequately defined. We aimed to determine …

Background Most individuals developing tuberculosis (TB) are working age adults living in
low- and middle-income countries (LMICs). The resulting disability and death impact …

Drug-resistant tuberculosis (DR-TB) threatens progress in the control of TB. Mathematical
models are increasingly being used to guide public health decisions on managing both …

The M72/AS01 E tuberculosis vaccine showed 50% (95%CI: 2–74%) efficacy in a phase 2B
trial in preventing active pulmonary tuberculosis disease, but potential cost-effectiveness of …

Background India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths
in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/…

Background Despite recent advances through the development pipeline, how novel tuberculosis
(TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/…

Introduction One in two patients developing tuberculosis (TB) in low-income and middle-income
countries (LMICs) faces catastrophic household costs. We assessed the potential …

Recently, two Phase 2B tuberculosis vaccine trials reported positive efficacy results in
adolescents and adults. However, experience in vaccinating these age groups is limited. We …